Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

NCT05896007 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

PCNSL

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Methotrexate
DRUG: Temozolomide

Sponsor

Ruijin Hospital